Aptamer Group is the developer of optimised aptamers for the life science industry using its proprietary Optimer® platform.
Optimer binders can be used as an antibody alternative to offer novel solutions and improvements to current processes across therapeutic, diagnostic, and research sectors. These binders are being applied as direct therapeutics and delivery vehicles for the targeted delivery of oligonucleotide and small molecule therapeutics to specific tissues, along with reagents to hit new targets and challenging tissues.
Offering rapid development in just weeks, controlled and tuneable binding kinetics to ensure desired end-use performance, Optimer binders are engineered to remove barriers to innovation across the life sciences.
Optimer binders are engineered to remove barriers to innovation and help make science unlimited.